AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 91 min read$IPSC

Carr Douglas sold $526 of IPSC

Carr Douglas (SVP Finance & Operations) sold 249 shares of Century Therapeutics, Inc. (IPSC) at $2.11 on 2026-06-08.

Original reporting
SEC EDGAR · Carr Douglas
Published Jun 9, 2026, 8:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 9, 2026, 8:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$IPSC
Neutral
medium confidence
Mentioned
$IPSC
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IPSCNeutralLow
01

Why it matters

The filing provides a new, primary-source datapoint on insider trading activity but does not disclose any new corporate event (e.g., guidance, trial results, financing, or regulatory action).

02

Market read

Traders may note the insider sale for sentiment monitoring, but it is unlikely to drive a material repricing without accompanying fundamental news.

03

What to watch

No 10b5-1 plan is cited, but the filing alone doesn’t reveal intent, future trading windows, or whether other insiders are buying/selling.

Relevance 3/10Novelty 2/10Timing: Filed 2026-06-09 (covers sale dated 2026-06-08)

Background

This is a SEC Form 4 insider transaction disclosure for Century Therapeutics, Inc. (IPSC).

Company-level read

Ticker impact

$IPSCNeutralMedium confidence
Context

Century Therapeutics (IPSC) disclosed an officer open-market sale: Carr Douglas sold 249 shares for $525.64 on 2026-06-08 via Form 4.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The transaction is modest in dollar value and does not include new company-specific operational/regulatory/financial information.

Market effects

Sector

No clear sector read-through from a single small insider sale.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

The sale may be liquidity-driven (taxes/diversification) and not a bearish signal, especially given the small size.

Key entities

  • insider
    Carr Douglas

    SVP Finance & Operations at Century Therapeutics; reported an open-market sale of 249 shares.

  • issuer
    Century Therapeutics, Inc.

    Issuer of the securities sold; insider transaction disclosed on SEC EDGAR.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

IPSC insider trading history →

Related articles

OCT 2
$IPSCMedAI 8/10

Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026

Century Therapeutics, Inc. (IPSC) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026 Data demonstrated scalable production, in vivo function and immune evasion, and updated progress toward clinical dosing of CNTY-813, Centur

SEC EDGAR 8-K2 min
OCT 2
$IPSCMedAI 8/10

Century Therapeutics presents diabetes therapy data at EASD

Century Therapeutics (NASDAQ:IPSC) presented data on CNTY-813, a diabetes therapy, at the EASD meeting. The therapy showed long-term glycemic control in mouse models and successful engraftment in rats. The company plans to submit an IND application in Q4 2026, with clinical data expected in H2 2027, according to the press release.

investing.com2 min
OCT 2
$IPSCMed

Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026

Century Therapeutics (NASDAQ: IPSC) presented nonclinical data for CNTY-813, its iPSC-derived islet replacement therapy for type 1 diabetes, at EASD 2026. Data showed glycemic control in diabetic mice, scalable production, and immune evasion. The company expects to submit an IND application in Q4 2026 and anticipates initial clinical data in 2H 2027.

globenewswire.com3 min
AUG 18
$IPSCHighAI 8/10

Century Targets FDA Filing for Diabetes Cell Therapy

Century Therapeutics (NASDAQ: IPSC) aims to file for FDA approval of its diabetes cell therapy, CNTY-813, in Q4 2026, with initial human data expected in 2027. The company reported $197.2M in cash as of Q2 2026, sufficient to fund operations into Q1 2029. Preclinical results showed promising glucose control and immune evasion, but clinical outcomes are not guaranteed. Century also advances CNTY-308, a CAR-iT cell therapy, with IND-enabling work on track for 2026. Q2 R&D expenses decreased 27% to

mychesco.com3 min